NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

中樞神經系主導療藥的全球市場:各疾病、各地區、各國 - 市場機會及未來預測

Global Central Nervous System Therapeutic Market : Analysis By Disease, By Region, By Country : Opportunities and Forecast - By Region, By Country

出版商 Azoth Analytics 商品編碼 817528
出版日期 內容資訊 英文 214 Pages
訂單完成後即時交付
價格
中樞神經系主導療藥的全球市場:各疾病、各地區、各國 - 市場機會及未來預測 Global Central Nervous System Therapeutic Market : Analysis By Disease, By Region, By Country : Opportunities and Forecast - By Region, By Country
出版日期: 2019年03月31日內容資訊: 英文 214 Pages
簡介

本報告提供全球中樞神經系統 (CNS) 治療藥的市場相關分析,整體市場規模趨勢預測 (過去5年份、今後6年份) ,及各疾病、各地區 (主要國家)的詳細趨勢,主要的推動及阻礙市場要素,市場向心力與競爭環境,企業簡介等相關調查。

第1章 分析方法

第2章 摘要整理

第3章 策略建議

第4章 中樞神經系統 (CNS) 治療藥市場:產品概要

第5章 全球中樞神經系主導療藥市場:成長率與其預測

  • 市場規模的成果值 (以金額為準,過去5年份)
  • 市場規模的預測值 (以金額為準,今後6年份)

第6章 全球中樞神經系主導療藥市場:各部門 (各疾病)的分析

  • 市場規模、佔有率:各疾病
    • 各疾病市場佔有率:成果值 (以金額為準)
    • 各疾病市場佔有率:預測值 (以金額為準)
  • 癌症
  • 神經血管障礙
  • 神經退化性疾病
  • 神經症 (心理健康)
  • 外傷
  • 感染疾病

第7章 全球中樞神經系主導療藥市場:各地區的分析

  • 市場規模、佔有率:各地區
    • 各地區市場佔有率:成果值 (以金額為準)
    • 各地區市場佔有率:預測值 (以金額為準)
  • 北美市場:成長率與其預測 - 全部區域
    • 市場規模:成果值 (以金額為準,過去5年份)
    • 市場規模:預測值 (以金額為準,今後6年份)
    • 市場規模,各類型:成果值 (以金額為準,過去5年份)
    • 市場規模,各類型:預測值 (以金額為準,今後6年份)
  • 北美市場:成長率與其預測 - 美國,加拿大
    • 各國的市場規模 (以金額為準,總計11年份)
  • 歐洲市場:成長率與其預測 - 全部區域
  • 歐洲市場:成長率與其預測 - 英國,德國
  • 亞太地區市場:成長率與其預測 - 全部區域
  • 亞太地區市場:成長率與其預測 - 中國,日本,印度
  • 其他的國家 (RoW)的市場:成長率與其預測 - 全部區域
  • 其他的國家 (RoW)的市場:成長率與其預測 - 巴西

第8章 市場動態:全球中樞神經系主導療藥市場

  • 推動市場要素
  • 阻礙市場要素

第9章 市場趨勢:全球中樞神經系主導療藥市場

第10章 波特的五力分析

第11章 SWOT分析

第12章 供應鏈分析

第13章 政策、法規環境

第14章 企業簡介

  • Biogen
  • Pfizer
  • Teva Pharmaceuticals
  • Novartis
  • Johnson & Johnson
  • Shire
  • Merck & Co.
  • AstraZeneca
  • 大塚製藥
  • Eli Lilly
目錄

Executive Summary

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Central nervous System Therapeutic Market. The report analyzes the Central Nervous System Therapeutic Market By Disease (Cancer, Neurovascular, Degenerative disorder, Mental Health, Trauma, Infection). The Central Nervous System Therapeutic Market has been analyzed By Region (North America, Europe, Asia Pacific and Rest of the World) and By Country (US, Canada, UK, Germany, China, Japan, India, and Brazil) for the historical period of 2014-2018 and the forecast period of 2019-2024.

According to Azoth Analytics research report "Global Central Nervous System Therapeutic Market : Analysis By Disease (Cancer, Neurovascular, Degenerative disorder, Mental Health, Trauma and Infection), By Region, By Country (2019 Edition): Opportunities and Forecast (2014-2024) - By Region (North America, Europe, APAC, ROW), By Country (US, Canada, UK, Germany, China, Japan, India, Brazil)", global market is projected to display a robust growth represented by a CAGR of 6.80% during 2019 - 2024.

The mental health has been witnessing growth at a noteworthy rate over the past few years backed by rise in stress and depression among people as well as increasing awareness and acceptance amongst people about mental health. Amongst the regions, Asia Pacific accounts for the largest regional share in the global central nervous system therapeutic market in 2018. Key factors driving the robust growth rate of Asia Pacific region include rising geriatric population along with increasing incidences of neurodegenerative diseases, increase in chronic ailments and growing per capita healthcare expenditure worldwide.

The report titled "Global Central Nervous System Therapeutic Market: Analysis By Disease (Cancer, Neurovascular, Degenerative disorder, Mental Health, Trauma and Infection), By Region, By Country (2019 Edition): Opportunities and Forecast (2014-2024) - By Region (North America, Europe, APAC, ROW), By Country (US, Canada, UK, Germany, China, Japan, India, Brazil)" has covered and analyzed the potential of Global Central Nervous System Therapeutic market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global central nervous system therapeutic market. Additionally, the report also highlights market entry strategies for various companies across the globe.

Scope of the Report

Global Central Nervous System Therapeutic Market (Actual Period: 2014-2018, Forecast Period: 2019-2024

  • Global Central Nervous System Therapeutic Market - Size, Growth, Forecast
  • By Disease (Cancer, Neurovascular, Degenerative disorder, Mental Health, Trauma, Infection)

Regional Markets - North America, Europe, APAC and Rest of the World (Actual Period: 2014-2018, Forecast Period: 2019-2024)

  • Central Nervous System Therapeutic Market - Size and Growth
  • By Disease (Cancer, Neurovascular, Degenerative disorder, Mental Health, Trauma, Infection)

Country Analysis - US, Canada, UK, Germany, China, Japan, India, Brazil (Actual Period: 2014-2018, Forecast Period: 2019-2024)

  • Central Nervous System Therapeutic Market - Size and Growth
  • By Disease (Cancer, Neurovascular, Degenerative disorder, Mental Health, Trauma, Infection)

Other Report Highlights

  • Market Dynamics - Drivers and Restraints
  • Market Trends
  • Porter Five Force Analysis
  • Policy and Regulatory Landscape
  • Competitive Landscape
  • Company Analysis - Biogen, Pfizer, Teva Pharmaceuticals, Novartis, Johnson & Johnson, Shire, Merc & Co, AstraZeneca, Otsuka Pharmaceutical, Eli Lilly.

Customization of the Report

The report could be customized according to the client's specific research requirements. No additional cost will be required to pay for limited additional research.

Table of Contents

1. Research Methodology

2. Executive Summary

3. Strategic Recommendations

4. Central Nervous System Therapeutic Market: Product Outlook

5. Global Central Nervous System Therapeutic Market: Growth and Forecast

  • 5.1 By Value (2014-2018)
  • 5.2 By Value (2019-2024)

6. Global Central Nervous System Therapeutic Market: Segment Analysis

  • 6.1 Global Central Nervous System Therapeutic Market Size, By Type: Breakdown (%)
    • 6.1.1 Global Central Nervous System Therapeutic Market Size, By Type, 2018 (%)
    • 6.1.2 Global Central Nervous System Therapeutic Market Size, By Type, 2024 (%)
  • 6.2 Global Cancer Market, By Value (2014-2024)
  • 6.3 Global Neurovascular Market, By Value (2014-2024)
  • 6.4 Global Neurodegenerative disorder Market, By Value (2014-2024)
  • 6.5 Global Mental Health Market, By Value (2014-2024)
  • 6.6 Global Trauma Market, By Value(2014-2024)
  • 6.7 Global Infection Market, By Value (2014-2024)

7. Global Central Nervous System Therapeutic Market: Regional Analysis

  • 7.1 Global Central Nervous System Therapeutic Market Size, By Region: Breakdown (%)
    • 7.1.1 Global Central Nervous System Therapeutic Market Size, By Region, 2018 (%)
    • 7.1.2 Global Central Nervous System Therapeutic Market Size, By Region, 2024 (%)
  • 7.2 North America Central Nervous System Therapeutic Market: Growth and Forecast
    • 7.2.1 By Value (2014-2018)
    • 7.2.2 By Value (2019-2024)
    • 7.2.3 By Type, By Value (2014-2018)
    • 7.2.4 By Type, By Value (2019-2024)
  • 7.3 North America Central Nervous System Therapeutic Market: Country Analysis (U.S and Canada)
    • 7.3.1 U.S Central Nervous System Therapeutic Market, By Value (2014-2024)
    • 7.3.2 Canada Central Nervous System Therapeutic Market, By Value (2014-2024)
  • 7.4 Europe Central Nervous System Therapeutic Market: Growth and Forecast
    • 7.4.1 By Value (2014-2018)
    • 7.4.2 By Value (2019-2024)
    • 7.4.3 By Type, By Value (2014-2018)
    • 7.4.4 By Type, By Value (2019-2024)
  • 7.5 Europe Central Nervous System Therapeutic Market: Country Analysis (U.K and Germany)
    • 7.5.1 U.K Central Nervous System Therapeutic Market, By Value (2014-2024)
    • 7.5.2 Germany Central Nervous System Therapeutic Market, By Value (2014-2024)
  • 7.6 APAC Central Nervous System Therapeutic Market: Growth and Forecast
    • 7.6.1 By Value (2014-2018)
    • 7.6.2 By Value (2019-2024)
    • 7.6.3 By Type, By Value (2014-2018)
    • 7.6.4 By Type, By Value (2019-2024)
  • 7.7 APAC Central Nervous System Therapeutic Market: Country Analysis (Japan, India and China)
    • 7.7.1 China Central Nervous System Therapeutic Market, By Value (2014-2024)
    • 7.7.2 Japan Central Nervous System Therapeutic Market, By Value (2014-2024)
    • 7.7.3 India Central Nervous System Therapeutic Market, By Value (2014-2024)
  • 7.8 ROW Central Nervous System Therapeutic Market: Growth and Forecast
    • 7.8.1 By Value (2014-2018)
    • 7.8.2 By Value (2019-2024)
    • 7.8.3 By Type, By Value (2014-2018)
    • 7.8.4 By Type, By Value (2019-2024)
  • 7.9 ROW Central Nervous System Therapeutic Market: Country Analysis (Brazil)
    • 7.9.1 Brazil Central Nervous System Therapeutic Market, By Value (2014-2024)

8. Global Central Nervous System Therapeutic Market Dynamics

  • 8.1 Global Central Nervous System Therapeutic Market Drivers
  • 8.2 Global Central Nervous System Therapeutic Market Restraints

9. Global Central Nervous System Therapeutic Market Trends

10. Porter Five Force Analysis

11. SWOT Analysis

12. Supply Chain Analysis

13. Policy and Regulatory Landscape

14. Company Profiles

  • 14.1 Biogen
  • 14.2 Pfizer
  • 14.3 Teva Pharmaceuticals
  • 14.4 Novartis
  • 14.5 Johnson & Johnson
  • 14.6 Shire
  • 14.7 Merck & Co.
  • 14.8 AstraZeneca
  • 14.9 Otsuka Pharmaceutical
  • 14.10 Eli Lilly

List of Figures

  • Figure 1: Flowchart of Nervous System
  • Figure 2: Tumor Grade Descriptions
  • Figure 3: Overview of major subcategories of central nervous system disorders
  • Figure 4: Global Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)
  • Figure 5: Global Central Nervous System Therapeutic Market Size, By Value, Forecast, 2019-2024 (USD Billion)
  • Figure 6: Global Overweight Population (Age above 18), 2015-2018 (% of total)
  • Figure 7: Global Overweight Population (Age above 18), By Sex, 2018 (% of total)
  • Figure 8: Smoking Prevalence Among Adults, By Gender, 2015
  • Figure 9: Cigarette Sales Share, By Region, 2017 (% of total)
  • Figure 10: Distributions of persons aged 60 years or above by region in millions, 2015 and 2030F
  • Figure 11: Global Aged Population (Above 65), 2014-2018 (% of total)
  • Figure 12: Regions with dedicated policies for neurological disorders, In 2017, ( In %)
  • Figure 13: Countries with dedicated policies for neurological disorders, Based on income group, In 2017, In %
  • Figure 14: Healthcare Expenditure (Share of GDP), By Selected Country, 2014-2018 (In %)
  • Figure 15: Expected Global Medical Spending in 2020, By Product Type, (% of Total)
  • Figure 16: Expected Global Medical Spending in 2020, By Region, (% of Total)
  • Figure 17: Most frequent neurological diseases reported in primary care, In 2017
  • Figure 18: Most frequent neurological diseases reported in primary care, In 2017
  • Figure 19: Regional Expected Healthcare Industry Growth Rate By Year 2020
  • Figure 20: GDP Per Capita PPP, By Region, 2018 (in Thousand USD)
  • Figure 21: Projected global population aged 60 years & above (In Billions)
  • Figure 22: Global Central Nervous System Therapeutic Market Size, By Type, 2017 (In %)
  • Figure 23: Global Central Nervous System Therapeutic Market Size, By Type, 2023 (In %)
  • Figure 24: Global Cancer Market, By Value, 2014-2018 (USD Billion)
  • Figure 25: Global Cancer Market, By Value, Forecast, 2019-2024(USD Billion)
  • Figure 26: Global Neurovascular Market, By Value, 2014-2018 (USD Billion)
  • Figure 27: Global Neurovascular Market, By Value, Forecast, 2019-2024(USD Billion)
  • Figure 28: Global Neurodegenerative Market, By Value, 2014-2018 (USD Billion)
  • Figure 29: Global Neurodegenerative Market, By Value, Forecast, 2019-2024(USD Billion)
  • Figure 30: Global Neurodegenerative Therapeutic Market Size, By Value, 2018 (%)
  • Figure 31: Global Neurodegenerative Therapeutic Market Size, By Value, 2024 (%)
  • Figure 32: Global Mental Health Market, By Value, 2014-2018 (USD Billion)
  • Figure 33: Global Mental Health Market, By Value, Forecast, 2019-2024(USD Billion)
  • Figure 34: Global Trauma Market, By Value, 2014-2018 (USD Billion)
  • Figure 35: Global Trauma Market, By Value, Forecast, 2019-2024(USD Billion)
  • Figure 36: Global TraumaTherapeutic Market Size, By Value, 2018 (%)
  • Figure 37: Global TraumaTherapeutic Market Size, By Value, 2024 (%)
  • Figure 38: Global Brain Infection Market, By Value, 2014-2018 (USD Billion)
  • Figure 39: Global Brain Infection Market, By Value, Forecast, 2019-2024(USD Billion)
  • Figure 40: Global Healthcare Landscape, By Select Region
  • Figure 41: Global Central Nervous System Therapeutic Market Size, By Region, 2018 (%)
  • Figure 42: Global Central Nervous System Therapeutic Market Size, By Region, 2024 (%)
  • Figure 43: North America Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)
  • Figure 44: North America Central Nervous System Therapeutic Market Size, By Value, Forecast, 2019-2024 (USD Billion)
  • Figure 45: North America Population Ages 65 and above, 2012-2017 (% of Total)
  • Figure 46: North America Healthcare Cost Per Capita, 2017 (USD)
  • Figure 47: Most frequent neurological diseases reported in primary care, In North America, 2017
  • Figure 48: North America GDP, 2012-2017 (USD Trillion)
  • Figure 49: North America GDP per capita, current prices, 2013-2023F (In USD)
  • Figure 50: North America Central Nervous System Therapeutic Market: By Type, By Value, 2014-2018 (USD Billion)
  • Figure 51: North America Central Nervous System Therapeutic Market: By Type, By Value, 2019E-2024F (USD Billion)
  • Figure 52: U.S. Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)
  • Figure 53: U.S. Central Nervous System Therapeutic Market Size, By Value, 2019-2024 (USD Billion)
  • Figure 54: Most costly neurological disorders in United States, In 2017
  • Figure 55: U.S., Per Capita Expenditure on Healthcare, 2012-2018 (In USD)
  • Figure 56: Proportion of people with Alzheimer disease, In United States, In 2017
  • Figure 57: Projected number of people with Alzheimer disease aged 65 and older, In United States, In million, In 2017
  • Figure 58: Aggregate cost of care for Alzheimer, By payer, In United States, In 2017
  • Figure 59: U.S., Population ages 65 and above, Forecast (In Millions)
  • Figure 60: U.S., GDP (Current USD), 2014-2018 (In USD Trillion)
  • Figure 61: Canada Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)
  • Figure 62: Canada Central Nervous System Therapeutic Market Size, By Value, 2019-2024 (USD Billion)
  • Figure 63: Canada, Population ages 65 and above, 2012-2017 (% of total)
  • Figure 64: Canada, Expenditure on Health as a share of GDP, 2012-2017 (in %)
  • Figure 65: Canada, Per Capita Healthcare Expenditure, 2012-2017 (USD)
  • Figure 66: Incidence, mortality and survival statistics for brain cancer in Canada, In 2017
  • Figure 67: Prevalence of brain cancer in Canada
  • Figure 68: Europe Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)
  • Figure 69: Europe Central Nervous System Therapeutic Market Size, By Value, Forecast, 2019-2024 (USD Billion)
  • Figure 70: Most frequent neurological diseases reported in primary care, In Europe, 2017
  • Figure 71: Distribution of Schizophrenia patients worldwide, In 2017, In thousands
  • Figure 72: Per Capita Health Expenditure, By Select Country, 2017 (USD)
  • Figure 73: European Union, Population ages 65 and above, 2013-2017 (% of total)
  • Figure 74: European Country Population Aged 65 and Above, 2012-2017 (% of Total)
  • Figure 75: GDP, Europe Region, By Select Country, 2017 (In Trillion USD)
  • Figure 76: Europe Central Nervous System Therapeutic Market: By Type, By Value, 2014-2018 (USD Billion)
  • Figure 77: Europe Central Nervous System Therapeutic Market: By Type, By Value, 2019E-2024F (USD Billion)
  • Figure 78: U.K. Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)
  • Figure 79: U.K. Central Nervous System Therapeutic Market Size, By Value, 2019-2024 (USD Billion)
  • Figure 80: Most costly neurological disorders in United Kingdom, In 2017
  • Figure 81: Proportion of people with symptoms of mental disorders in United Kingdom
  • Figure 82: Proportion of symptoms of mental disorder, By sex, In 2017, In United Kingdom
  • Figure 83: U.K, Health Expenditure, (% of GDP), 2012-2017 (USD)
  • Figure 84: U.K, Population Ages 65 and Above (% of total), 2012-2017
  • Figure 85: UK, Healthcare Infrastructure Related Statistics
  • Figure 86: U.K, Spending on Healthcare, 2015 & 2040, (USD Per Person)
  • Figure 87: Germany Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)
  • Figure 88: Germany Central Nervous System Therapeutic Market Size, By Value, 2019-2024 (USD Billion)
  • Figure 89: Germany, Population ages 65 and above, 2012-2017 (% total)
  • Figure 90: Germany, Spending on Healthcare, 2015 & 2040E, (USD Per Person)
  • Figure 91: Germany, Healthcare Related Statistics, 2017
  • Figure 92: APAC Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)
  • Figure 93: APAC Central Nervous System Therapeutic Market Size, By Value, Forecast, 2019-2024 (USD Billion)
  • Figure 94: GDP Per Capita in APAC, By Select Country, 2016 (In USD)
  • Figure 95: Population ages 65 and above, By Select Country, 2017 (% of total)
  • Figure 96: Men Smoking Prevalence in Asia, 2016, (% of Total Population)
  • Figure 97: Most frequent neurological diseases reported in primary care, In Asia Pacific, 2017
  • Figure 98: APAC Central Nervous System Therapeutic Market: By Type, By Value, 2014-2018 (USD Billion)
  • Figure 99: APAC Central Nervous System Therapeutic Market: By Type, By Value, 2019E-2024F (USD Billion)
  • Figure 100: China Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)
  • Figure 101: China Central Nervous System Therapeutic Market Size, By Value, 2019-2024 (USD Billion)
  • Figure 102: China, Smoking Prevalence, Age 15+, % of Total Population, 2012-2016
  • Figure 103: China, Tobacco Attributable Deaths, 2030
  • Figure 104: China, Total Population, 2013-2021F (In Billion)
  • Figure 105: China, GDP Growth Per Year, 2015-2019 (In %)
  • Figure 106: China, Share of Urban Population, 2012-2017 (In %)
  • Figure 107: China Healthcare Expenditure Outlook (2017) (%)
  • Figure 108: China, Population Above 65 (% of Total), 2013-2017
  • Figure 109: Japan Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)
  • Figure 110: Japan Central Nervous System Therapeutic Market Size, By Value, 2019-2024 (USD Billion)
  • Figure 111: Japan, Population ages 65 and above, 2012-2017 (% of total)
  • Figure 112: Japan, Smoking Prevalence, Age 15+, 2012-2016, (% of Total Prevalence)
  • Figure 113: Japan Healthcare Expenditure Outlook (%)
  • Figure 114: India Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)
  • Figure 115: India Central Nervous System Therapeutic Market Size, By Value, 2019-2024 (USD Billion)
  • Figure 116: India, Population ages 65 and above, 2013-2017
  • Figure 117: India, Total Population, 2013-2023F (In Billion)
  • Figure 118: India, Smoking Prevalence, Age 15+, 2012-2016, (% of Total)
  • Figure 119: India, Share of Urban Population, 2012-2017 (In %)
  • Figure 120: India, GDP Growth Per Year, 2015-2019 (In %)
  • Figure 121: ROW Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)
  • Figure 122: ROW Central Nervous System Therapeutic Market Size, By Value, Forecast, 2019-2024 (USD Billion)
  • Figure 123: GDP Per Capita in ROW, By Select Country, 2013 (In USD)
  • Figure 124: GDP Per Capita in ROW, By Select Country, 2017 (In USD)
  • Figure 125: Latin America and Caribbean, Population ages 65 and above 2012-2017(% of total)
  • Figure 126: Middle East and North Africa, Population ages 65 and above (% of total)
  • Figure 127: Most frequent neurological diseases reported in primary care, In Africa, In 2017
  • Figure 128: Methods of financing neurological care
  • Figure 129: ROW Central Nervous System Therapeutic Market: By Type, By Value, 2014-2018 (USD Billion)
  • Figure 130: ROW Central Nervous System Therapeutic Market: By Type, By Value, 2019E-2024F (USD Billion)
  • Figure 131: Brazil Central Nervous System Therapeutic Market Size, By Value, 2014-2018 (USD Billion)
  • Figure 132: Brazil Central Nervous System Therapeutic Market Size, By Value, 2019-2024 (USD Billion)
  • Figure 133: Brazil, Population ages 65 and above, 2012-17 (% of total)
  • Figure 134: Brazil, GDP, 2012-2017 (In USD Trillion)
  • Figure 135: Brazil health expenditure as a share of GDP, 2016
  • Figure 136: Biogen, Sales Revenue, 2013-2017 (USD Billion)
  • Figure 137: Biogen, Sales, By Business Segment, FY ended March 2017 (%)
  • Figure 138: Biogen, Sales, By Geographic region, FY ended March 2017 (%)
  • Figure 139: Pfizer, Sales Revenue, 2013-2017 (USD million)
  • Figure 140: Pfizer, Sales, By Business Segment, FY ended March 2017 (In %)
  • Figure 141: Pfizer, By Geographic Region, FY ended March 2017 (In %)
  • Figure 142: Teva Pharmaceuticals, Net Sales, 2014-2018 (In Million USD)
  • Figure 143: Teva Pharmaceuticals, Net Sales, By Business Sector, 2018 (In %)
  • Figure 144: Teva Pharmaceuticals, Net Sales, By Geographic Region, 2018 (In %)
  • Figure 145: Novartis, Sales Revenue, 2013-2017 (USD Million)
  • Figure 146: Novartis, Sales, By Business Segment, FY ended March 2018 (%)
  • Figure 147: Novartis, By Region, FY ended March 2018 (%)
  • Figure 148: Johnson & Johnson, Sales Revenue, 2013-2017 (USD Million)
  • Figure 149: Johnson & Johnson , Sales, By Business Segment, FY ended March 2018 (%)
  • Figure 150: Johnson & Johnson, By Region, FY ended March 2018 (%)
  • Figure 151: Shire, Sales Revenue, 2015-2017 (USD Million)
  • Figure 152: Shire, Sales, By Business Segment, FY ended March 2017 (%)
  • Figure 153: Shire, By Region, FY ended March 2017 (%)
  • Figure 154: Merck & Co., Sales Revenue, 2013-2017 (USD Million)
  • Figure 155: Merck & Co. , Sales, By Business Segment, FY ended March 2017 (%)
  • Figure 156: Merck & Co., By Region, FY ended March 2017 (%)
  • Figure 157: AstraZeneca, Sales Revenue, 2013-2017 (USD Million)
  • Figure 158: AstraZeneca, Sales, By Business Segment, FY ended March 2017 (%)
  • Figure 159: AstraZeneca, By Region, FY ended March 2017 (%)
  • Figure 160: Otsuka Pharmaceutical, Sales, By Business Segment, FY ended March 2017 (%)
  • Figure 161: Otsuka Pharmaceutical, By Region, FY ended March 2017 (%)
  • Figure 162: Eli Lilly, Sales Revenue, 2013-2017 (USD Million)
  • Figure 163: Eli Lilly, Sales, By Business Segment, FY ended March 2017 (%)
  • Figure 164: Eli Lilly, By Region, FY ended March 2017 (%)

List of Tables

  • Table A: Top 10 diseases causing the most deaths worldwide, In 2017
  • Table B: Smoking prevalence worldwide, In 2017, By Sex, In %
  • Table C: Facts about mental health in United Kingdom
  • Table D: Global Access to Healthcare Index, Ranking of Select Countries in Asia Pacific Region, 2017 (score out of 10)
  • Table E: Rate of suicides worldwide, In 2017, In number
  • Table F: National List of Essential medicines in India, By Select Disease, In 2017
  • Table G: Healthcare spending pattern in Brazil (In USD)